INNA-051

INNA-051 is a nasal spray developed by Ena Respiratory, an Australian biotech company. It is designed to boost the natural immune response and reduce the growth and spread of viruses, including the SARS-CoV-2 virus responsible for the COVID-19 pandemic.

Overview

INNA-051 is a synthetic small molecule that stimulates the innate immune system, the body's first line of defense against viral infections. It is administered as a nasal spray and is intended to be used in the early stages of infection to prevent the virus from taking hold and spreading throughout the body.

Mechanism of Action

INNA-051 works by stimulating the body's innate immune system. When administered, it triggers a natural immune response, causing the body to produce a range of antiviral proteins. These proteins can inhibit the replication of viruses, reducing their ability to spread and cause disease.

Clinical Trials

As of 2021, INNA-051 is in the preclinical stage of development. Early studies have shown promising results, with the treatment reducing the viral load of SARS-CoV-2 in animal models by up to 96%. Further trials are needed to confirm these results in humans.

Potential Impact

If successful, INNA-051 could provide a new way to manage viral infections, including COVID-19. It could be used alongside vaccines to provide additional protection, particularly for those who are unable to receive a vaccine due to health reasons.

See Also

• COVID-19 pandemic
• SARS-CoV-2
• Innate immune system
• Viral replication

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian